Alpha Cognition Inc. announced its financial results for the first quarter ended March 31, 2025, reporting total revenue of $2.93 million, a significant increase from zero in the prior-year period. This revenue included $346,929 from ZUNVEYL product sales and $2.58 million from licensing revenue, primarily from the CMS Asia-Pacific deal.
Operating expenses for Q1 2025 totaled $6.62 million, an increase from $4.41 million in Q1 2024, driven by investments in commercial operations. Research and development expenses decreased to $407,511, reflecting a shift towards commercial activities following ZUNVEYL's approval.
The net loss for the quarter significantly narrowed to $2.01 million, or $0.13 per share, compared to a net loss of $5.00 million, or $0.87 per share, in Q1 2024. As of March 31, 2025, Alpha Cognition held approximately $45.5 million in unrestricted cash and cash equivalents, and successfully repaid its $911,463 promissory note to NLS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.